aripiprazole has been researched along with brexpiprazole in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (33.33) | 24.3611 |
| 2020's | 28 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jaśkowska, J; Kułaga, D; Satała, G | 1 |
| He, Y; Liu, Y; Shen, J; Shi, W; Wang, Y; Wang, Z; Wu, C; Wu, S; Yang, F; Zheng, W | 1 |
| Cheng, J; Fan, L; Liu, R; Tan, L; Wang, H; Wang, S; Yan, W; Yu, J | 1 |
| Futamura, T; Hashimoto, K; Ishima, T; Kikuchi, T; Ohgi, Y; Yoshimi, N | 1 |
| Citrome, L | 2 |
| Stahl, SM | 1 |
| Baker, RA; Citrome, L; Nagamizu, K; Ota, A; Perry, P; Weiller, E | 1 |
| Baker, RA; Fava, M; Matsushima, Y; Okame, T; Perry, P; Weiller, E | 1 |
| Castle, D; Hope, J; Keks, NA | 1 |
| Aladeen, T; Capote, H; Lee, Y; McIntyre, RS; Rainka, M; Rong, C; Westphal, E | 1 |
| Burudpakdee, C; Greene, M; Hartry, A; Seetasith, A | 1 |
| Baker, RA; Duffy, RA; Gwin, KK; McQuade, RD; Weiller, E; Weiss, C; Zhang, P | 1 |
| Frampton, JE | 1 |
| Limandri, BJ | 1 |
| Citrome, LL; Manning, JS; McIntosh, D; McIntyre, RS | 1 |
| Cummings, OT; Enders, JR; Feng, S; McIntire, G; McIntire, T; Strickland, EC | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Broder, MS; Chang, E; Greene, M; Houle, CR; Tarbox, MH; Waters, HC; Yan, T | 1 |
| Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Sakuma, K | 1 |
| Antoun Reyad, A; Girgis, E; Mishriky, R | 1 |
| Copolov, D; Hope, J; Keks, N; McLennan, H; Meadows, G; Schwartz, D | 1 |
| Boku, S; Fujiyama, H; Fukuhara, R; Kanno, T; Kawahara, K; Sugawara, H; Takebayashi, M; Tanaka, H | 1 |
| Espay, AJ; Gupta, HV; Sharma, VD | 1 |
| Aoki, K; Inada, K; Ishigooka, J; Iwashita, S; Kojima, Y; Niidome, K; Yamada, S | 1 |
| Alefishat, E; Aloum, L; Baltatu, OC; Petroianu, GA | 1 |
| Futamura, T; Hirose, T; Kikuchi, T; Maeda, K; McQuade, RD; Suzuki, M | 1 |
| Aguirre, C; Garcia, M; Lertxundi, U; Morera-Herreras, T; Zazu, L | 1 |
| Bellagamba, S; Orsolini, L; Salvi, V; Volpe, U | 1 |
| De Ponti, F; Fusaroli, M; Giunchi, V; Menchetti, M; Poluzzi, E; Raschi, E; Rimondini Giorgini, R | 1 |
| Atik, H; Ferraiolo, M; Hanson, J; Hermans, E; Koener, B; Ponthot, R | 1 |
| De Ronchi, D; Fabbri, C; Fanelli, G; Lippi, M; Serretti, A | 1 |
| Borroto-Escuela, DO; Callado, LF; Fuxe, K; García-Sevilla, JA; Kinoshita, M; Meana, JJ; Mikami, M; Odagaki, Y | 1 |
| Husak, N; Laudone, TW; Leonard, JB | 1 |
| Carvalho, AF; Hsu, CW; Hsu, TW; Liang, CS; Thompson, T; Tsai, TC; Tseng, PT; Yu, CL | 1 |
| Keightley, P; Naughton, S; Nelson, J; O'Hara, K | 1 |
| Abuelazm, H; Crump, CJ; El-Mallakh, RS; Good, ME | 1 |
| Iyo, M; Kanahara, N; Kimura, H; Kogure, M; Koyoshi, S; Nakata, Y; Oiwa, T; Saito, T; Sasaki, T; Yamasaki, F; Yanagisawa, Y; Yoshida, T | 1 |
| Bauknecht, P; Baumann, P; Kuzin, M; Schoretsanitis, G | 1 |
| Cain, K; Chung, I; Hardy, RE; Hirst, J; Loh, SHY; MacFarlane, M; Martins, LM; Morone, N; Panman, L; Pryde, KR; Serreli, R; Soleilhavoup, C; Travaglio, M; Yu, Y | 1 |
| Li, M; Li, W; Qiu, Z; Wang, J; Wu, H | 1 |
| Munayco Maldonado, GM; Schwartz, TL | 1 |
16 review(s) available for aripiprazole and brexpiprazole
| Article | Year |
|---|---|
Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections, Intramuscular; Paliperidone Palmitate; Piperazines; Quinolones; Schizophrenia; Tetrabenazine; Thiophenes; Valine | 2016 |
Brexpiprazole: a new leaf on the partial dopamine agonist branch.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Dopamine Agonists; Humans; Quinolones; Schizophrenia; Thiophenes | 2018 |
Brexpiprazole: A Review in Schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Approval; Humans; Japan; Quinolones; Schizophrenia; Serotonin Receptor Agonists; Thiophenes; United States | 2019 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Humans; Network Meta-Analysis; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain | 2020 |
Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome | 2020 |
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Thiophenes | 2020 |
The action of aripiprazole and brexpiprazole at the receptor level in
Topics: Aripiprazole; Hiccup; Humans; Neurotransmitter Agents; Quinolones; Thiophenes | 2021 |
Discovery research and development history of the dopamine D
Topics: Aripiprazole; Depressive Disorder, Major; Dopamine; Dopamine Agonists; Humans; Quinolones; Research; Thiophenes; United States | 2021 |
The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Dopamine Antagonists; Humans; Polypharmacy; Psychotic Disorders; Quinolones; Thiophenes | 2022 |
Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Haloperidol; Humans; Mania; Olanzapine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2023 |
Aripiprazole, brexpiprazole, and cariprazine can affect milk supply: Advice to breastfeeding mothers.
Topics: Animals; Aripiprazole; Breast Feeding; Dopamine Agonists; Female; Humans; Milk; Mothers | 2023 |
Narrative review of the advances in the pharmacotherapeutic management of juvenile-onset schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Humans; Lurasidone Hydrochloride; Quetiapine Fumarate; Schizophrenia; Young Adult | 2023 |
Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Humans; Schizophrenia | 2023 |
Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Network Meta-Analysis; Olanzapine; Quetiapine Fumarate | 2023 |
Differentiating the third generation of antipsychotics: a focus on lumateperone's similarities and differences.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Schizophrenia; Weight Gain | 2024 |
2 trial(s) available for aripiprazole and brexpiprazole
| Article | Year |
|---|---|
The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes; Treatment Outcome; Weight Gain | 2016 |
Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Topics: Antidepressive Agents; Aripiprazole; Bupropion; Central Nervous System Stimulants; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Impulsive Behavior; Male; Middle Aged; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Sleep; Thiophenes; Treatment Outcome | 2017 |
24 other study(ies) available for aripiprazole and brexpiprazole
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of novel serotonin and dopamine receptor ligands being 6-bromohexyl saccharine derivatives.
Topics: Antidepressive Agents; Binding Sites; Dopamine Antagonists; Drug Evaluation, Preclinical; Ligands; Models, Molecular; Molecular Structure; Piperazines; Protein Binding; Receptors, Dopamine; Receptors, Serotonin; Saccharin; Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Thermodynamics | 2019 |
Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Pyridines; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Structure-Activity Relationship; Triazoles | 2020 |
2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Dopamine Agonists; Drug Design; Drug Evaluation, Preclinical; Half-Life; Humans; Mice; Mice, Inbred ICR; Receptors, Dopamine D2; Stereoisomerism; Structure-Activity Relationship | 2021 |
Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors.
Topics: Animals; Aripiprazole; Boron Compounds; Dose-Response Relationship, Drug; Drug Synergism; Fluorobenzenes; HSP90 Heat-Shock Proteins; Inositol 1,4,5-Trisphosphate Receptors; Macrocyclic Compounds; Nerve Growth Factor; Neurites; Oxazoles; PC12 Cells; Piperazines; Piperidines; Pyridines; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Serotonin Agents; Thiophenes | 2015 |
The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Humans; Piperazines; Quinolones; Schizophrenia; Thiophenes | 2015 |
Mechanism of action of brexpiprazole: comparison with aripiprazole.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Thiophenes | 2016 |
The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; New York; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Thiophenes; Treatment Outcome; Young Adult | 2018 |
Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
Topics: Adult; Age Factors; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Female; Health Expenditures; Health Resources; Health Services; Humans; Insurance Claim Review; Lurasidone Hydrochloride; Male; Middle Aged; Models, Econometric; Quetiapine Fumarate; Quinolones; Residence Characteristics; Retrospective Studies; Sex Factors; Socioeconomic Factors; Thiophenes; Time-to-Treatment | 2018 |
The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Longitudinal Studies; Male; Meta-Analysis as Topic; Middle Aged; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain | 2018 |
Clinical Use of Dopamine Modulators as Third-Generation Antipsychotic Agents.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine D2 Receptor Antagonists; Humans; Quinolones; Receptors, Dopamine D2; Schizophrenia; Serotonin Antagonists; Thiophenes | 2019 |
Activating and Sedating Properties of Medications Used for the Treatment of Major Depressive Disorder and Their Effect on Patient Functioning.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Arousal; Comorbidity; Delayed-Action Preparations; Depressive Disorder, Major; Drug Approval; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Practice Patterns, Physicians'; Quality of Life; Quetiapine Fumarate; Quinolones; Sleep Initiation and Maintenance Disorders; Thiophenes | 2019 |
A Dilute and Shoot LC-MS/MS Method for Antipsychotics in Urine.
Topics: Antipsychotic Agents; Aripiprazole; Chromatography, Liquid; Drug Monitoring; Humans; Limit of Detection; Quinolones; Tandem Mass Spectrometry; Thiophenes | 2020 |
Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Female; Health Care Costs; Hospitalization; Humans; Lurasidone Hydrochloride; Male; Medicaid; Medicare; Middle Aged; Olanzapine; Paliperidone Palmitate; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Thiophenes; United States | 2020 |
Combination therapy of brexpiprazole and aripiprazole for an adolescent patient with a first episode of schizophrenia: A case report.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes | 2020 |
Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia.
Topics: Adrenergic beta-Antagonists; Aged; Aripiprazole; Clonazepam; Deprescriptions; Depressive Disorder; Drug Substitution; GABA Modulators; Humans; Male; Parkinsonian Disorders; Pelvis; Propranolol; Quinolones; Serotonin Agents; Tardive Dyskinesia; Tetrabenazine; Thiophenes; Treatment Failure; Valine | 2020 |
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Japan; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome | 2021 |
Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study.
Topics: Antipsychotic Agents; Aripiprazole; Piperazines; Quinolones; Thiophenes | 2021 |
A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Quinolones; Schizophrenia; Schizophrenia, Treatment-Resistant; Thiophenes; Young Adult | 2022 |
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.
Topics: Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agonists; Humans; Hyperphagia; Lurasidone Hydrochloride; Olanzapine; Pharmacovigilance; Quinolones; Receptors, Serotonin; Thiophenes; United States; United States Food and Drug Administration | 2022 |
Receptor density influences the recruitment bias of aripiprazole and brexpiprazole at the dopamine D
Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Humans; Receptors, Dopamine D2 | 2022 |
Agonistic properties of a series of psychotropic drugs at 5-HT
Topics: Animals; Aripiprazole; Brain; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Lurasidone Hydrochloride; Psychotropic Drugs; Rats; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin Receptor Agonists; Vortioxetine | 2023 |
A descriptive study of aripiprazole, brexpiprazole, and cariprazine exposures in children ages 0 to 5 years reported to United States poison centers.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Male; Poisons; Retrospective Studies; United States | 2023 |
Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Humans; Psychotic Disorders; Retrospective Studies; Schizophrenia | 2023 |
The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drosophila melanogaster; Electron Transport; Mice | 2023 |